Stay informed and ready to meet both everyday challenges and long-term planning and policy-making goals, with focused news, practical information, and strategic insights on all HR-related developments.
NEW YORK--A federal judge May 31 gave final approval to a $99 million settlement of a nationwide wage and hour class action on overtime claims by more than 7,000 Novartis Pharmaceuticals Corp. sales representatives (In re Novartis Wage & Hour Litig., S.D.N.Y., No. 06-MD-1794, settlement approved 5/31/12).
Judge Paul A. Crotty of U.S. District Court for the Southern District of New York approved the settlement following a fairness hearing held the same day. In January, he granted preliminary approval to the settlement, which stems from a pair of 2006 lawsuits filed under the Fair Labor Standards Act and California and New York laws (30 HRR 91, 1/30/12).
The final order and judgment allocated $70,758,500 to settlement awards for class members; $27,608,000 to attorneys' fees; $400,000 to reimbursement of litigation fees; and $233,500 to class representatives and others involved in the case.
The $233,500 included compensatory damages and service awards ranging from $20,000 to $40,000 for each of five named plaintiffs.
In February 2011, the U.S. Supreme Court declined to review a decision by the U.S. Court of Appeals for the Second Circuit that the Novartis pharmaceutical representatives were covered by FLSA overtime protections (29 HRR 234, 3/7/11).
But a decision by the Supreme Court is pending in a separate case, Christopher v. SmithKlineBeecham Corp. (U.S., No. 11-204), raising the issue of whether the FLSA's outside sales exemption covers pharmaceutical sales representatives (29 HRR 1295, 12/5/11). The case was argued in April, and a decision is expected by the end of the high court's term in June (30 HRR 425, 4/23/12).
The sales representatives' law firm in the Novartis case, Sanford Wittels & Heisler in Washington, D.C., pointed to the pending case as one of the reasons for settling the Novartis case.
In reaching the settlement, the law firm “was keenly aware that if the Supreme Court ruled that pharmaceutical representatives are exempt outside salespersons, the plaintiffs in the Novartis case would not be able to recover any overtime pay, notwithstanding the Second Circuit's favorable ruling,” according to a statement on the firm's website.
The firm also said it considered the “serious danger” that, if there were a change in administrations after the November presidential election, the Labor Department “would take the position that pharmaceutical sales representatives are exempt from overtime pay.”
Representatives of the plaintiffs and Novartis did not respond to requests for comment on the judge's approval. In a joint statement they issued when the preliminary approval was granted, the two sides said they had decided not to await a Supreme Court decision in the SmithKlineBeecham case.
By John Herzfeld
Text of the settlement is available at http://op.bna.com/dlrcases.nsf/r?Open=kpin-8uutgm.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)